Prolyl hydroxylase inhibitors
US10035779B2 · kind B2 · utility
2Cited by
5References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2016 |
| Grant date | Jul 31, 2018 |
| Priority date | — |
| Expiry date | Jun 20, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.